Results 151 to 160 of about 2,077 (188)

New developments in the management of vulvovaginal atrophy: a comprehensive overview

Expert Opinion on Pharmacotherapy, 2023
Proper recognition and individualized therapy of vulvovaginal atrophy (VVA) is paramount.Assessment of VVA should be performed using several questionnaires in combination with wet mount microscopy to determine Vaginal Cell Maturation Index (VCMI) and infections.
Donders, Gilbert G.G., Donders, Francesca H.W.V.   +1 more
openaire   +3 more sources

Advances in the treatment of vulvovaginal atrophy

Expert Review of Obstetrics & Gynecology, 2013
Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching, dysuria and dyspareunia, only a quarter of symptomatic women are believed to seek medical attention. Until recently, treatments for vulvovaginal atrophy were limited to
Jill M Krapf, Zoe R Belkin, Andrew T Goldstein   +2 more
openaire   +1 more source

The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review

Climacteric, 2017
11 páginasObjectives: To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women. Methods: A systematic literature review was performed.
C. E. Pinzón, Pinzón Flórez, Carlos Eduardo, A. M. Osorio, O. I. Restrepo, Rueda, C., Osorio, A. M., Restrepo Castro, Olga Isabel, C. Rueda, Avellaneda, A. C., A. C. Avellaneda   +9 more
exaly   +2 more sources

Prasterone: A Review in Vulvovaginal Atrophy

Drugs & Aging, 2019
Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this population. Intravaginal prasterone (Intrarosa®) is a
openaire   +2 more sources

Treatment of Dyspareunia Secondary to Vulvovaginal Atrophy

Nursing for Women's Health, 2014
Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause.
openaire   +2 more sources

Managing vulvovaginal atrophy after breast cancer

Post Reproductive Health, 2018
Cancer treatment may result in loss of ovarian function through surgical removal of the ovaries, chemotherapy or radiation. While menopausal symptoms, such as hot flushes, night sweats, sleep disturbance, memory concerns and mood issues can be extremely bothersome to some women going through menopause naturally, women who undergo an induced menopause ...
Jenifer, Sassarini, Mahesh, Perera, Keith, Spowart, Kay, McAllister, Judith, Fraser, Ros, Glasspool, Rosie, Harrand, Marina, Chitoni, Sheila, Stallard, Mary-Ann, Lumsden   +9 more
openaire   +2 more sources

Rehabilitation of patients with vulvovaginal atrophy

Journal of Medical Rehabilitation
Background. Genitourinary syndrome of menopause (GSM) is characterized by a number of pathological changes, in particular urological disorders, vulvovaginal atrophy (VVA) and sexual dysfunction. They are commonly accompanied by decreased quality of life (QoL) and often require medical intervention. At the same time, the steps taken to effectively solve
P. L. Khazan, A. N. Mnatsakanyan, D. I. Korabelnikov, D. M. Ampilogova, D. A. Petrenko   +4 more
openaire   +1 more source

Ospemifene for the Treatment of Vulvovaginal Atrophy and Dyspareunia in Postmenopausal Women

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
Vulvovaginal atrophy (VVA) and dyspareunia are common problems experienced by postmenopausal women, although few seek treatment. Symptom‐based therapies include nonhormonal vaginal lubricants, vaginal moisturizers, low‐dose vaginal estrogen, and systemic estrogen.
Amber N, McLendon, Valerie B, Clinard, C Brock, Woodis   +2 more
openaire   +2 more sources

A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy

Menopause, 2018
Abstract Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support ...
Robin J, Bell, Farwa, Rizvi, Rakabul M, Islam, Susan R, Davis   +3 more
openaire   +2 more sources

Laser Treatment for Vulvovaginal Atrophy

2019
Laser therapy has a therapeutic role for different medical conditions and most recently has gained interest as a non-hormonal treatment for vulvovaginal atrophy or genitourinary syndrome of menopause (GSM). Both microablative fractional CO2 laser and the second-generation non-ablative vaginal Er:YAG laser (VEL) can alleviate the symptoms of dryness and
openaire   +1 more source